As of 2025-09-18, the Relative Valuation of Blueprint Medicines Corp (BPMC) is (33.35) USD. This relative valuation is based on P/E multiples. With the latest stock price at 129.46 USD, the upside of Blueprint Medicines Corp based on Relative Valuation is -125.8%.
The range of the Relative Valuation is (32.51) - (33.66) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 13.5x - 14.4x | 13.9x |
| Forward P/E multiples | 13.5x - 14.0x | 13.8x |
| Fair Price | (32.51) - (33.66) | (33.35) |
| Upside | -125.1% - -126.0% | -125.8% |
| Date | P/E |
| 2025-07-17 | -53.76 |
| 2025-07-16 | -53.69 |
| 2025-07-15 | -53.72 |
| 2025-07-14 | -53.72 |
| 2025-07-11 | -53.69 |
| 2025-07-10 | -53.71 |
| 2025-07-09 | -53.38 |
| 2025-07-08 | -53.32 |
| 2025-07-07 | -53.32 |
| 2025-07-03 | -53.30 |
| 2025-07-02 | -53.24 |
| 2025-07-01 | -53.30 |
| 2025-06-30 | -53.23 |
| 2025-06-27 | -53.20 |
| 2025-06-26 | -53.22 |
| 2025-06-25 | -53.26 |
| 2025-06-24 | -53.26 |
| 2025-06-23 | -53.32 |